Ipragliflozin clinical trials
Also written ASP1941.
How each study uses ipragliflozin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
48 studies that test it; most in 2010 (15)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 15 |
| 2011 | 8 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 46 · Other 2
Astellas Pharma Inc (38) · Astellas Pharma Europe B.V. (3) · Astellas Pharma Korea, Inc. (2) · Merck Sharp & Dohme LLC (2) · Seoul National University Bundang Hospital (1) · Yonsei University (1) · Astellas Pharma Global Development, Inc. (1)
Often tested with
Tested in the same studies.
Glimepiride (2) · Nateglinide (1) · DPP-4 inhibitors (1) · Insulin (1) · Furosemide (1) · Mitiglinide (1) · Miglitol (1) · Sitagliptin (1)
Related medicines
As reviewed, each with the page that says it.
- One of SGLT2 inhibitors source
Studies
Open first, then newest update. How each study uses ipragliflozin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 48
- A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01054092Written as ipragliflozin
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01225081Written as ipragliflozin
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01242202Written as ipragliflozin
- A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01316107Written as ipragliflozin
- A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes PatientsCompletedPhase 3Astellas Pharma IncNCT01057628Written as ipragliflozin
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01135433Written as ipragliflozin
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01242228Written as ipragliflozin
- A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal ImpairmentCompletedPhase 3Astellas Pharma IncNCT01316094Written as ASP1941
- A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes MellitusCompletedPhase 2Astellas Pharma IncNCT01071850Written as ipragliflozin
- A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes MellitusCompletedPhase 2Astellas Pharma IncNCT01117584Written as ipragliflozin
- A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.CompletedPhase 2Astellas Pharma IncNCT00790660Written as ASP1941
- Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin TherapyCompletedPhase 4Astellas Pharma IncNCT02847091Written as Ipragliflozin
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes PatientsCompletedPhase 3Astellas Pharma IncNCT01505426Written as ASP1941
- A Study of ASP1941 in Participants With Type 2 Diabetes MellitusCompletedPhase 2Astellas Pharma IncNCT00621868Written as ipragliflozin
- A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal ImpairmentCompletedPhase 1Astellas Pharma IncNCT01097681Written as ASP1941
- A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes MellitusCompletedPhase 3Astellas Pharma IncNCT02897219Written as ipragliflozin
- Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes MellitusCompletedPhase 2Astellas Pharma IncNCT02529449Written as ASP1941
- A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and SitagliptinCompletedPhase 3Astellas Pharma Korea, Inc.NCT02452632Written as ASP1941
- A Study of ASP1941 in Japanese Patients With Type 2 Diabetes MellitusCompletedPhase 1Astellas Pharma IncNCT01023945Written as ASP1941
- A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes MellitusTerminatedPhase 3Astellas Pharma IncNCT01514838Written as ASP1941
See all 48 studies that test ipragliflozin →
Given beside what is tested · 1 — ipragliflozin is usual care or a partner of the new treatment
Codes
What other systems call ipragliflozin · ClinicalTrials.gg INT006079
- MeSH (NLM) C572941ipragliflozinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3N2N8OOR7XIPRAGLIFLOZINConfirmed FDA, NLM, Wikidata
- Wikidata Q17193526ipragliflozinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166685IpragliflozinOne source FDA
- DrugBank DB11698One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C572941 | ipragliflozin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3N2N8OOR7X | IPRAGLIFLOZIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q17193526 | ipragliflozin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166685 | Ipragliflozin | One source FDA |
| DrugBank | DB11698 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.